Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ONCY's Cash to Debt is ranked higher than
95% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. ONCY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ONCY' s 10-Year Cash to Debt Range
Min: 45.91  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
ONCY's Interest Coverage is ranked higher than
90% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONCY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONCY' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -0.01
M-Score: -3.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -92.34
ONCY's ROE (%) is ranked lower than
79% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. ONCY: -92.34 )
Ranked among companies with meaningful ROE (%) only.
ONCY' s 10-Year ROE (%) Range
Min: -164.19  Med: -57.64 Max: -26.92
Current: -92.34
-164.19
-26.92
ROA (%) -75.98
ONCY's ROA (%) is ranked lower than
80% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. ONCY: -75.98 )
Ranked among companies with meaningful ROA (%) only.
ONCY' s 10-Year ROA (%) Range
Min: -125.21  Med: -52.26 Max: -25.07
Current: -75.98
-125.21
-25.07
ROC (Joel Greenblatt) (%) -3313.88
ONCY's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. ONCY: -3313.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ONCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -15749.15  Med: -6880.93 Max: -250.97
Current: -3313.88
-15749.15
-250.97
EBITDA Growth (3Y)(%) -19.30
ONCY's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. ONCY: -19.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ONCY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -19.3  Med: -1.30 Max: 42.6
Current: -19.3
-19.3
42.6
EPS Growth (3Y)(%) -20.00
ONCY's EPS Growth (3Y)(%) is ranked lower than
65% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. ONCY: -20.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ONCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -20  Med: 4.00 Max: 21.9
Current: -20
-20
21.9
» ONCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ONCY Guru Trades in Q4 2013

First Eagle Investment 427,200 sh (unchged)
Jim Simons 19,200 sh (-39.05%)
» More
Q1 2014

ONCY Guru Trades in Q1 2014

Jim Simons 23,600 sh (+22.92%)
First Eagle Investment 427,200 sh (unchged)
» More
Q2 2014

ONCY Guru Trades in Q2 2014

Jim Simons 36,000 sh (+52.54%)
First Eagle Investment 188,600 sh (-55.85%)
» More
Q3 2014

ONCY Guru Trades in Q3 2014

Jim Simons Sold Out
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ONCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 10.89
ONCY's Forward P/E is ranked higher than
85% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. ONCY: 10.89 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 3.12
ONCY's P/B is ranked higher than
65% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ONCY: 3.12 )
Ranked among companies with meaningful P/B only.
ONCY' s 10-Year P/B Range
Min: 1.25  Med: 4.95 Max: 18.75
Current: 3.12
1.25
18.75
EV-to-EBIT -3.58
ONCY's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. ONCY: -3.58 )
Ranked among companies with meaningful EV-to-EBIT only.
ONCY' s 10-Year EV-to-EBIT Range
Min: -22.6  Med: -5.00 Max: 0.5
Current: -3.58
-22.6
0.5
Current Ratio 7.24
ONCY's Current Ratio is ranked higher than
64% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ONCY: 7.24 )
Ranked among companies with meaningful Current Ratio only.
ONCY' s 10-Year Current Ratio Range
Min: 2.21  Med: 10.71 Max: 142.02
Current: 7.24
2.21
142.02
Quick Ratio 7.24
ONCY's Quick Ratio is ranked higher than
65% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. ONCY: 7.24 )
Ranked among companies with meaningful Quick Ratio only.
ONCY' s 10-Year Quick Ratio Range
Min: 2.21  Med: 10.71 Max: 142.02
Current: 7.24
2.21
142.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.25
ONCY's Price/Net Cash is ranked higher than
83% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. ONCY: 3.25 )
Ranked among companies with meaningful Price/Net Cash only.
ONCY' s 10-Year Price/Net Cash Range
Min: 2.63  Med: 7.45 Max: 24.08
Current: 3.25
2.63
24.08
Price/Net Current Asset Value 3.25
ONCY's Price/Net Current Asset Value is ranked higher than
80% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. ONCY: 3.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ONCY' s 10-Year Price/Net Current Asset Value Range
Min: 2.56  Med: 7.10 Max: 22.36
Current: 3.25
2.56
22.36
Price/Tangible Book 3.12
ONCY's Price/Tangible Book is ranked higher than
71% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. ONCY: 3.12 )
Ranked among companies with meaningful Price/Tangible Book only.
ONCY' s 10-Year Price/Tangible Book Range
Min: 2.21  Med: 6.85 Max: 22.36
Current: 3.12
2.21
22.36
Earnings Yield (Greenblatt) (%) -27.90
ONCY's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. ONCY: -27.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ONCY' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 208.6  Med: 410.40 Max: 2116.4
Current: -27.9
208.6
2116.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ONC.Canada, ONY.Germany,
Oncolytics Biotech Inc was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. The Company is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The Company focused on the development of oncolytic viruses for use as cancer therapeutics. Its product, REOLYSIN, a proprietary formulation of the human reovirus, is in late stage (Phase III) clinical testing in head and neck cancers.
» More Articles for NAS:ONCY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic... Jul 06 2015
Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic... Jul 06 2015
Oncolytics Biotech® Inc. Collaborators Present Final Data from REO 017 Clinical Study in Pancreatic... Jul 06 2015
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International... Jun 15 2015
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International... Jun 15 2015
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® Preclinical Data at the 9th International... Jun 15 2015
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders Jun 12 2015
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders Jun 12 2015
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders Jun 12 2015
Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of... Jun 09 2015
Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of... Jun 09 2015
Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of... Jun 09 2015
Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN® Jun 08 2015
Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN® Jun 08 2015
Oncolytics Biotech® Inc. Provides Update at AGM on Planned Registration Program for REOLYSIN® Jun 08 2015
/C O R R E C T I O N -- Oncolytics Biotech Inc./ Jun 06 2015
/C O R R E C T I O N -- Oncolytics Biotech Inc./ Jun 06 2015
Oncolytics Biotech® Inc. Announces Details of 2015 Annual Meeting of Shareholders Jun 05 2015
Oncolytics Biotech® Inc. Announces Details of 2015 Annual Meeting of Shareholders Jun 05 2015
Oncolytics Biotech® Inc. Announces Details of 2015 Annual Meeting of Shareholders Jun 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK